AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncytial respiratory virus (SRV) in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1 in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV-7 in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of FC in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (IL 1 beta, TNF beta, GM-CSF) in children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of children with FC (G1)
Number of subjects: 65
Study 8906369 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM and IgA levels in children with FC (G1)
Number of subjects: 65
Study 8265876 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive loads increased from 0 to 24 cm H2O/l/s in 1, 3 or 6 steps or decreased in 6 steps
Number of subjects: 18
Study 4005428 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG plus androgen
Number of subjects: 121
Study 4005428 — intervention group
Group type: COMPARATOR
Intervention: ATG plus placebo
Number of subjects: 121
Study 31950923 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg silodosin for 10 days
Number of subjects: 76
Study 31950923 — intervention group
Group type: COMPARATOR
Intervention: No silodosin uptake
Number of subjects: 76
Study 30232854 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 100
Study 30232854 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (Metformin)
Number of subjects: 100
Study 30232854 — intervention group
Group type: COMPARATOR
Intervention: Simple lifestyle intervention
Number of subjects: 100
Study 28281972 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy WBRT + simvastatin 80 mg/day
Number of subjects: 50
Study 28281972 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy WBRT
Number of subjects: 50
Study 24872255 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing (n = 20)
Number of subjects: 39
Study 24872255 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular mid-septum (RVS) pacing (n = 19)
Number of subjects: 39
Study 22305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perceived difficulties in sexual activity at 1 month after discharge
Number of subjects: 792
Study 22305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perceived difficulties in sexual activity at 18 months after discharge
Number of subjects: 792
Study 22305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without difficulties at 1 month who developed difficulties during follow-up
Number of subjects: 792
Study 22305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with perceived difficulties in sexual activity
Number of subjects: 792
Study 22305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who perceive difficulties in sexual activity
Number of subjects: 792
Study 20633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Glaucoma Probability Score (GPS)
Number of subjects: 438
Study 20633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis (MRA)
Number of subjects: 438
Study 20633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereometric parameters
Number of subjects: 438
Study 20633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Photograph-based horizontal cup-to-disc ratio
Number of subjects: 438
Study 18388038 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 39
Study 18388038 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/d
Number of subjects: 39
Study 16041191 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 U subcutaneously (s.q.) twice daily
Number of subjects: 0
Study 16041191 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 U subcutaneously (s.q.) three times daily
Number of subjects: 0
Study 16041191 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 0
Study 16041191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16041191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0
Study 12446055 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET imaging before revascularization
Number of subjects: 82
Study 12446055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PET and clinical parameters
Number of subjects: 82
Study 10336532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg p.o.)
Number of subjects: 12
Study 10336532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8938155 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg immunoprophylaxis (10,000 IU monthly)
Number of subjects: 52
Study 8938155 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 52
Study 1927823 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal phase‐contrast MR angiography
Number of subjects: 33
Study 1927823 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐of‐flight MR angiography
Number of subjects: 33
Study 1927823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined axial and coronal phase‐contrast images
Number of subjects: 33
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylmianserin
Number of subjects: 0
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hydroxymianserin
Number of subjects: 0
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin-N-oxide
Number of subjects: 0
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (racemate)
Number of subjects: 0
Study 6824558 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylmianserin and 8-hydroxymianserin
Number of subjects: 0
Study 30798010 — intervention group
Group type: EXPERIMENTAL
Intervention: dlPFC group (n = 17)
Number of subjects: 38
Study 30798010 — intervention group
Group type: COMPARATOR
Intervention: VC/control group (n = 21)
Number of subjects: 38
Study 30798010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 30340765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg BID
Number of subjects: 1694
Study 30340765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg BID
Number of subjects: 1694
Study 30340765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1694
Study 27048437 — intervention group
Group type: EXPERIMENTAL
Intervention: vBloc therapy
Number of subjects: 84
Study 27048437 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 84
Study 25254898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulgarian squat on stable surface
Number of subjects: 15
Study 25254898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulgarian squat on unstable surface
Number of subjects: 15
Study 25254898 — intervention group
Group type: COMPARATOR
Intervention: Regular squat on stable surface
Number of subjects: 15
Study 25254898 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable surfaces
Number of subjects: 15
Study 25254898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulgarian squat and regular squat
Number of subjects: 15
Study 22366365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate injection (once a week for 3 weeks)
Number of subjects: 105
Study 22366365 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (once)
Number of subjects: 105
Study 22366365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate injection
Number of subjects: 105
Study 22366365 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 105
Study 20736504 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 3201
Study 20736504 — intervention group
Group type: COMPARATOR
Intervention: Patients without LVH
Number of subjects: 3201
Study 20736504 — intervention group
Group type: COMPARATOR
Intervention: CKD patients without LVH
Number of subjects: 3201
Study 20736504 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD patients with LVH
Number of subjects: 3201
Study 20736504 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without CKD but with LVH
Number of subjects: 3201
Study 20736504 — intervention group
Group type: COMPARATOR
Intervention: Patients without CKD or LVH
Number of subjects: 3201
Study 17372796 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention for smoking cessation counseling
Number of subjects: 588
Study 17372796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored intervention)
Number of subjects: 588
Study 15737299 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program and clinical decision support system (CDSS) based on GINA recommendations
Number of subjects: 198
Study 15737299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study 11891668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem slow releasing formulation (90 mg)
Number of subjects: 7
Study 11891668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem moderate releasing formulation (90 mg)
Number of subjects: 7
Study 11891668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem fast releasing formulation (90 mg)
Number of subjects: 7
Study 11891668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem oral solution (90 mg)
Number of subjects: 7
Study 11891668 — intervention group
Group type: COMPARATOR
Intervention: Dissolution method using USP Apparatus II with purified water
Number of subjects: 7
Study 9865999 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 1396
Study 9865999 — intervention group
Group type: COMPARATOR
Intervention: ML 250 IUD
Number of subjects: 1396
Study 8588962 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable implants (self‐reinforced poly‐L‐lactide wire combined with self‐reinforced polyglycolide screw or self‐reinforced poly‐L‐lactide plug)
Number of subjects: 35
Study 8588962 — intervention group
Group type: COMPARATOR
Intervention: Metallic implants (tension band wiring, Kirschner wire and metallic cerclage wire)
Number of subjects: 35
Study 2577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (Rengasil)
Number of subjects: 0
Study 2577748 — intervention group
Group type: COMPARATOR
Intervention: Piritramide (Dipidolor)
Number of subjects: 0
Study 787015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 787015 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 30467071 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (Diet HF)
Number of subjects: 282
Study 30467071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (Diet LF)
Number of subjects: 282
Study 28390502 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐ruminative style
Number of subjects: 0
Study 28390502 — intervention group
Group type: COMPARATOR
Intervention: Problem‐solving style
Number of subjects: 0
Study 28390502 — intervention group
Group type: COMPARATOR
Intervention: Distracting style
Number of subjects: 0
Study 26022314 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R1, CRP, and age
Number of subjects: 39
Study 26022314 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline analytes
Number of subjects: 39
Study 26022314 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual biomarkers
Number of subjects: 39
Study 23707271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 40
Study 23707271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21775106 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg
Number of subjects: 216
Study 21775106 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg
Number of subjects: 216
Study 21775106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 19467177 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (minimum, 0.016 mg/kg per IgE IU/mL every 4 weeks)
Number of subjects: 811
Study 19467177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811
Study 19467177 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 811
Study 16924047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatments (3 treatments at 1-month intervals)
Number of subjects: 32
Study 16924047 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study 15570138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 256
Study 15570138 — intervention group
Group type: COMPARATOR
Intervention: Exercise stretching control
Number of subjects: 256
Study 11230588 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 314
Study 11230588 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 314
Study 11230588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels (measured at various time points)
Number of subjects: 314
Study 9121357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1 or 2 mg twice daily
Number of subjects: 0
Study 9121357 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU‐200577 (active metabolite of Tolterodine)
Number of subjects: 0
Study 8435030 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 1126
Study 8435030 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 1126
Study 8435030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1126
Study 3300426 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane in nitrous oxide and oxygen
Number of subjects: 110
Study 3300426 — intervention group
Group type: COMPARATOR
Intervention: isoflurane in air and oxygen
Number of subjects: 110
Study 30630795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin calcium (subcutaneous injection for 5 days)
Number of subjects: 180
Study 30630795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-coagulant agent)
Number of subjects: 180
Study 27272517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (830 nm wavelength, power 150 mW, spot size 1 cm², 30 s per cm², energy density 4.5 J/cm²)
Number of subjects: 123
Study 27272517 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (placebo)
Number of subjects: 123
Study 26290002 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique Taxonomy version 1 (BCTTv1)
Number of subjects: 40
Study 23362338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (MBSR)
Number of subjects: 172
Study 23362338 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education intervention (NEP)
Number of subjects: 172
Study 23362338 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 172
Study 20197284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GDP fluid (Gambrosol trio)
Number of subjects: 80
Study 20197284 — intervention group
Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 80
Study 18676330 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus, administered at a flat weekly IV dose of 25 mg over 30-60 minutes
Number of subjects: 0
Study 18676330 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (standard therapy)
Number of subjects: 0
Study 16229958 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial substance use
Number of subjects: 2453
Study 16229958 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial number of substance using friends
Number of subjects: 2453
Study 16229958 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer substance use
Number of subjects: 2453
Study 16229958 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent substance use
Number of subjects: 2453
Study 12505817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of E-EPA
Number of subjects: 30
Study 12505817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10836215 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous continuous ante/retrograde cardioplegia
Number of subjects: 40
Study 10836215 — intervention group
Group type: COMPARATOR
Intervention: Retrograde continuous blood cardioplegia
Number of subjects: 40
Study 8801700 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 44
Study 8801700 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 44
Study 8801700 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance
Number of subjects: 44
Study 8801700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low S-citalopram due to carbamazepine treatment
Number of subjects: 44
Study 1353282 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0
Study 1353282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1353282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung surfactant (prepared from pigs)
Number of subjects: 0
Study 6377873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy
Number of subjects: 18
Study 6377873 — intervention group
Group type: COMPARATOR
Intervention: No cranial radiation therapy (Control)
Number of subjects: 18
Study 6377873 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire sample (with and without cranial radiation)
Number of subjects: 18
Study 6377873 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education levels
Number of subjects: 18
Study 31411338 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions led by a lay-tutor (former patient) in conjunction with physiotherapists; 10-week programme comprising 10 hours of education and 20 hours of physical exercise.
Number of subjects: 87
Study 31411338 — intervention group
Group type: COMPARATOR
Intervention: Control group led by 2 physiotherapists for the entire educational programme; 10-week programme comprising 10 hours of education and 20 hours of physical exercise.
Number of subjects: 87
Study 30559886 — intervention group
Group type: COMPARATOR
Intervention: Micro‐Osteoperforations (MOPs)
Number of subjects: 30
Study 30559886 — intervention group
Group type: COMPARATOR
Intervention: Low‐Level Laser Therapy (LLLT)
Number of subjects: 30
Study 30559886 — intervention group
Group type: COMPARATOR
Intervention: Combination of MOPs and LLLT
Number of subjects: 30
Study 27738237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study 27738237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 25013370 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (4.8 mg/day)
Number of subjects: 346
Study 25013370 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (8.2 mg/day)
Number of subjects: 346
Study 22665131 — intervention group
Group type: EXPERIMENTAL
Intervention: Beeswax and herbal oil cream
Number of subjects: 52
Study 22665131 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 52
Study 19483369 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program with monthly 30-min sessions for 6 months
Number of subjects: 149
Study 19483369 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (per-protocol analysis)
Number of subjects: 149
Study 19483369 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (subgroup analysis for low job control)
Number of subjects: 149
Study 19483369 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) program (subgroup analysis for high job control)
Number of subjects: 149
Study 19483369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study 18260374 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of pulmicort 2 ml plus 0.5% Aeuromycin solution 10 ml by oxygen driving force, once a day for 3 weeks
Number of subjects: 60
Study 18260374 — intervention group
Group type: COMPARATOR
Intervention: Rhinocort
Number of subjects: 60
Study 16127560 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with absolute alcohol
Number of subjects: 46
Study 16127560 — intervention group
Group type: COMPARATOR
Intervention: Banding ligation
Number of subjects: 46
Study 12399699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish applied to one tooth at baseline and after 3 and 6 months
Number of subjects: 16
Study 12399699 — intervention group
Group type: COMPARATOR
Intervention: Control tooth (no varnish applied)
Number of subjects: 16
Study 12399699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 16
Study 9952020 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 2
Study 9952020 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activation fragments (C4d, Bb, iC3b, SC5b‐9) measured via ELISA
Number of subjects: 2
Study 7587848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (up to 2 mg/day)
Number of subjects: 58
Study 7587848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 2245970 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy, dosage: around 2 IU/m2/day, duration: 12 months
Number of subjects: 0
Study 2245970 — intervention group
Group type: COMPARATOR
Intervention: GH administration to normal subjects
Number of subjects: 0
Study 35213 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 24
Study 35213 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 24